Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
Adverse events · Patients with histologically confirmed CGCG in one or both jaws and normal serum calcium and parathyroid hormone (PTH) levels
1 finding from 1 review
Adverse events were not described separately for each group. Trialists reported that adverse events were in most patients minimal and consisted of nausea, flushes and some dizziness. One patient had diarrhoea which…
1 study · 14 participants
GRADE not reported
Adverse events · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Serious adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic cout
Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Adverse events · daytime workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Withdrawals due to adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review